overview
Veracyte’s pioneering genomic tests are already setting new standards in thyroid and lung cancer diagnosis, where they have helped tens of thousands of patients avoid unnecessary surgery and other costly procedures. In late 2016, we launched our third product—the Envisia Genomic Classifier—to improve diagnosis of interstitial lung diseases, including idiopathic pulmonary fibrosis, without the need for surgery.
  • Afirma
    Reducing unnecessary surgeries in thyroid cancer diagnosis
    Learn more  >
  • Percepta
    Improving lung cancer screening and diagnosis
    Learn more  >
  • Envisia
    Clarifying the diagnosis of idiopathic pulmonary fibrosis
    Learn more  >